Xgeva (denosumab, AMG162)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Xgeva (also marketed as Prolia) |
| Generic Name: | denosumab |
| Code Name: | AMG162 |
| Company: | Amgen |
| FDA Clinical Phase: | 2 & 3 |
Description:
Prolia is a human monoclonal antibody which is being studied in the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma, and giant cell tumor of bone. Prolia is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal. In many bone loss conditions, RANKL overwhelms the body’s natural defense against bone destruction. Prolia therefore mimics the endogenous effects of osteoprotegerin.
Clinical Trials:
For a list of clinical trials studying BI-505 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for denosumab: http://www.amgen.com/science/pipe_denosumab.html
Source: Wikipedia, Denosumab, http://en.wikipedia.org/wiki/Denosumab (as of November 14, 2009)
Related Articles:
- Beacon BreakingNews – Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
- Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
- Phase 3 Trial Indicates Denosumab Delays Skeletal Related Events In Cancer Patients
- Prolia May Delay The Onset Of Bone Complications More Effectively Than Zometa In Multiple Myeloma Patients
- Beacon NewsFlashes – October 23, 2009
Leave a comment